Get started
Author

Francesca Protopapa

Observed names: F. Protopapa, PROTOPAPA, FRANCESCA
ORCID: 0000-0003-0529-4848
Observed ORCID: 0000-0003-0529-4848
OpenAlex ID: A5085645081
Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis
2021 · Beatrice Foglia, Erica Novo, et al. · Cells · 92
PDF
Liver fibrogenesis: un update on established and emerging basic concepts
2020 · Erica Novo, Claudia Bocca, et al. · Archives of Biochemistry and Biophysics · 22
SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease
2022 · Erica Novo, Andrea Cappon, et al. · Frontiers in Immunology · 18
The protease activated receptor 2 - CCAAT/enhancer-binding protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of non-alcoholic steatohepatitis
2024 · Gianmarco Villano, Erica Novo, et al. · Molecular Metabolism · 16
PDF
Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis
2024 · Beatrice Foglia, Salvatore Sutti, et al. · Frontiers in Immunology · 14
Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis
2022 · Claudia Bocca, Francesca Protopapa, et al. · Antioxidants · 13
PDF
Complex I Modulator BI4500 Reduces MASH by Limiting Oxidative Stress and Reprogramming Lipid Metabolism via AMPK in MCD Rats
2026 · Laura Giuseppina Di Pasqua, Sofia Lotti, et al. · Antioxidants · 6
PDF
SerpinB3 Upregulates Low-Density Lipoprotein Receptor-Related Protein (LRP) Family Members, Leading to Wnt Signaling Activation and Increased Cell Survival and Invasiveness
2023 · Santina Quarta, Andrea Cappon, et al. · Biology · 6
PDF
Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease
2026 · Riccardo Rizzo, Bianca S. Daraban, et al. · European Journal of Clinical Investigation
PDF
Circulating Pcsk9 Binds an Idl-like Lipoprotein
2026 · Riccardo Rizzo, Davide Barbarossa, et al. · Atherosclerosis
Pcsk9 Targeting Therapies Do Not Affect the Binding of Pcsk9 to Circulating Lipoproteins
2026 · Riccardo Rizzo, Davide Barbarossa, et al. · Atherosclerosis
Postprandial Vldl and Endothelial Inflammatory Activation: in Vitro Studies
2026 · Davide Barbarossa, Irina Tudorache, et al. · Atherosclerosis
Leukocyte Telomere Length in Hypercholesterolemic Patients: Differential Dynamics Between Clinical and Genetic Familial Hypercholesterolemia
2026 · Francesca Protopapa, Davide Barbarossa, et al. · Atherosclerosis
FRI-415 The mGluR5 blockade by MPEP inhibits PKC and triggers AMPK activation reducing hepatic steatosis in vitro
2025 · Michelangelo Trucchi, Laura Giuseppina Di Pasqua, et al. · Journal of Hepatology
FRI-381-YI Oncostatin M contributes to liver steatosis in experimental metabolic dysfunction - associated steatotic liver disease
2025 · Jessica Nurcis, Salvatore Sutti, et al. · Journal of Hepatology
Oncostatin M contributes to liver steatosis in experimental conditions of Metabolic dysfuntion - Associated Steatotic Liver Disease
2025 · J. Nurcis, S. Sutti, et al. · Digestive and Liver Disease
Activation of AMPK by a novel complex I modulator (CIM) reduces lipid accumulation and mitigates fibrosis in an in vivo model of MASLD
2025 · F. Protopapa, A. Ferrigno, et al. · Digestive and Liver Disease
MPEP combines mGluR5 inhibition and AMPK activation to reduce hepatic steatosis
2025 · M. Trucchi, L.G. Di Pasqua, et al. · Digestive and Liver Disease
THU-274 Targeting mitochondrial complex I modulates lipid metabolism, inflammation and hepatic fibrosis in a MCD-diet model of benign steatosis
2024 · Francesca Protopapa, Laura Giuseppina Di Pasqua, et al. · Journal of Hepatology
Inhibition of CCAT/enhancer-binding protein beta-serpinB3 axis by 1-piperidin propionic acid: a new targeted therapy for non-alcoholic steatohepatitis
2023 · Francesca Protopapa, Gianmarco Villano, et al. · Journal of Hepatology
The CCAAT/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for Non-Alcoholic Steatohepatitis treatment
2023 · A. Martini, G. Villano, et al. · Digestive and Liver Disease
The CCAAT/Enhancer-Binding Protein Beta - SerpinB3 Axis Inhibition as a Novel Strategy for Non-Alcoholic Steatohepatitis Treatment
2023 · Gianmarco Villano, Erica Novo, et al. · SSRN Electronic Journal
The role of histidine-rich glycoprotein in non alcoholic steatohepatitis-related experimental liver carcinogenesis
2022 · B. Foglia, S. Sutti, et al. · Digestive and Liver Disease
Oncostatin M, a novel profibrogenic mediator, is involved in the progression non-alcoholic fatty liver disease and stimulates migration of myofibroblasts
2020 · B. Foglia, E. Novo, et al. · Digestive and Liver Disease
A role for SerpinB3 and Oncostatin M in the progression of NASH
· PROTOPAPA, FRANCESCA · Institutional Research Information System University of Turin (University of Turin)
PDF
Works count: 25
Citation count: 187
H-index: 6
I10-index: 6
Year
Topic
Type